Progenics Pharmaceuticals (PGNX) : Traders are bullish on Progenics Pharmaceuticals (PGNX) as it has outperformed the S&P 500 by a wide margin of 6.78% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.15%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.32% in the last 1 week, and is up 6.21% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.61% and the 50-Day Moving Average is 0.91%.The 200 Day SMA reached 22.45%
Progenics Pharmaceuticals (NASDAQ:PGNX): After opening at $5.78, the stock dipped to an intraday low of $5.78 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.35 and the buying power remained strong till the end. The stock closed at $6.33 for the day, a gain of 10.66% for the day session. The total traded volume was 2,012,395. The stocks close on the previous trading day was $6.33.
Progenics Pharmaceuticals (PGNX) : The consensus price target for Progenics Pharmaceuticals (PGNX) is $11.5 for the short term with a standard deviation of $3.54. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $14, however, the pessimist price target for the company is $9.
Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).